Europe’s Biopharma Competitiveness: Building Commercial Resilience in an Era of Uncertainty
Europe’s biopharma sector is navigating regulatory change, pricing pressure, intensifying competition and fragmented markets. At the same time, the region has significant strengths in scientific innovation, research, talent and emerging biotech ecosystems. Success increasingly depends on how well companies connect those strengths to evidence generation, market access and commercialization.
In this article, Kipp Kreutzberg and Matt Krienick of Syneos Health explore how biopharma companies can build commercial resilience amid uncertainty. They make the case for planning across multiple markets early, preserving strategic options, learning from rare-disease commercialization and strengthening the capabilities needed to adapt as market conditions change.
You will learn how to:
- Expand competitiveness beyond scientific innovation by building capabilities across evidence generation, regulatory approval, market access and commercialization
- Plan for multiple market-entry scenarios and preserve strategic options as conditions evolve
- Apply a multi-market mindset early, accounting for differences in evidence requirements, reimbursement, clinical practice and patient access
- Draw lessons from rare-disease commercialization, including the value of focused stakeholder engagement and patient-centered evidence
- Treat compliance, governance and transparency as sources of competitive strength
- Build organizational flexibility to respond to regional opportunities and changing market demands
Read the full article in the European Biopharmaceutical Review BIO-Europe Supplement to explore how companies can strengthen their position in Europe’s changing biopharma landscape.
BIO-Europe Supplement, Autumn 2026, pages 42-45. © Samedan Ltd.
Related Content
Looking for exclusive insight?
